Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nanobiotix ( (NBTX) ) has shared an update.
On October 15, 2025, Nanobiotix announced its voting rights and share capital details as of September 30, 2025. The company reported 48,237,471 outstanding shares, with 50,318,257 theoretical voting rights and 50,296,139 exercisable voting rights. This update is crucial for stakeholders to understand the company’s current shareholder structure and voting power distribution.
The most recent analyst rating on (NBTX) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s stock score is primarily impacted by significant financial instability, marked by declining revenues and negative profitability. However, the stock’s strong technical momentum provides a counterbalance, suggesting potential short-term interest despite the company’s broader financial challenges. Valuation concerns persist due to the negative P/E ratio, reflecting non-profitability.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, focusing on innovative, physics-based therapeutic solutions. Founded in 2003, the company is listed on Euronext Paris and the Nasdaq Global Select Market, with subsidiaries in the United States. Nanobiotix owns over 25 patent families related to nanotechnology platforms in oncology, bioavailability, biodistribution, and central nervous system disorders.
Average Trading Volume: 60,089
Technical Sentiment Signal: Buy
Current Market Cap: $1.36B
Learn more about NBTX stock on TipRanks’ Stock Analysis page.